Key Stats for Moderna Stock
- Price change for Moderna stock on Mar 04: 16%
- $MRNA Share Price as of Mar. 04: $58
- 52-Week High: $60
- $MRNA Stock Price Target: $42
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Moderna (MRNA) stock is having its best day since January after the company settled a major patent dispute that had been hanging over the stock for years.
Late Tuesday, Moderna announced a settlement with Arbutus Biopharma and Genevant Sciences over patents related to its COVID vaccines.
The terms: a one-time payment of $950 million, with no future royalties.
If Moderna loses a separate Federal Circuit appeal arguing government contractor immunity, it could owe an additional $1.3 billion within 90 days.
That sounds like a lot. But investors were bracing for something far worse.
Analysts had been modeling potential liability of close to $5 billion — a number that would have raised serious concerns about Moderna’s balance sheet.
William Blair analyst Myles Minter called the outcome “better than feared.” Leerink Partners analyst Mani Foroohar said Moderna “dodged a bullet,” noting that the original worst-case scenario could have pushed the company “into acute distress.”
The settlement covers all worldwide litigation tied to Spikevax and mResvia, and also clears the path for future products like mNexspike and mCombriax.
That last part matters. Moderna has several important pipeline readouts coming in 2026, and investors needed to know the company was financially stable enough to see them through.
As a result of the settlement, Moderna now expects to end the year with $4.5–$5 billion in cash — a clear and concrete number that gives investors something to hold onto.
See analysts’ growth forecasts and price targets for Moderna stock (It’s free!) >>>
What the Market Is Telling Us About Moderna Stock
Moderna stock has been volatile this year. It ran up nearly 87% through late January, then sold off 34% by February 11th as legal uncertainty and FDA setbacks weighed on sentiment.
Today’s settlement removes the biggest single overhang.
From the Q4 earnings call, the underlying story is slowly improving.
Revenue came in at $1.9 billion for 2025, costs were cut by $2.2 billion year-over-year, and the company ended the year with $8.1 billion in cash before factoring in the settlement.
Management guided for up to 10% revenue growth in 2026, driven by international expansion and a second year of mNexspike sales.
The bigger catalyst ahead is the Phase 3 adjuvant melanoma data from the company’s cancer vaccine partnership with Merck.
Analysts are watching that closely.
Moderna stock still has plenty to prove. But today’s news removes a major risk and gives the company room to focus on what matters — its pipeline.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Moderna Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
